newsfilter
← Latest News
Business Wire·

PhaseBio Appoints William D. Humphries to Board of Directors

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of William D. Humphries to its boa